274 related articles for article (PubMed ID: 26282359)
21. Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder.
Korgaonkar MS; Goldstein-Piekarski AN; Fornito A; Williams LM
Mol Psychiatry; 2020 Jul; 25(7):1537-1549. PubMed ID: 31695168
[TBL] [Abstract][Full Text] [Related]
22. Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.
Maller JJ; Broadhouse K; Rush AJ; Gordon E; Koslow S; Grieve SM
Mol Psychiatry; 2018 Aug; 23(8):1737-1744. PubMed ID: 29133948
[TBL] [Abstract][Full Text] [Related]
23. Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report.
Braund TA; Palmer DM; Williams LM; Harris AWF
Psychol Med; 2020 Apr; 50(6):1032-1042. PubMed ID: 31023398
[TBL] [Abstract][Full Text] [Related]
24. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.
Shilyansky C; Williams LM; Gyurak A; Harris A; Usherwood T; Etkin A
Lancet Psychiatry; 2016 May; 3(5):425-35. PubMed ID: 26995298
[TBL] [Abstract][Full Text] [Related]
25. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial.
Tadić A; Wachtlin D; Berger M; Braus DF; van Calker D; Dahmen N; Dreimüller N; Engel A; Gorbulev S; Helmreich I; Kaiser AK; Kronfeld K; Schlicht KF; Tüscher O; Wagner S; Hiemke C; Lieb K
Eur Neuropsychopharmacol; 2016 Apr; 26(4):705-16. PubMed ID: 26899588
[TBL] [Abstract][Full Text] [Related]
26. Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.
Dreimüller N; Wagner S; Engel A; Braus DF; Roll SC; Elsner S; Tadić A; Lieb K
BMC Psychiatry; 2019 Jan; 19(1):24. PubMed ID: 30642308
[TBL] [Abstract][Full Text] [Related]
27. Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.
O'Connell CP; Goldstein-Piekarski AN; Nemeroff CB; Schatzberg AF; Debattista C; Carrillo-Roa T; Binder EB; Dunlop BW; Craighead WE; Mayberg HS; Williams LM
Am J Psychiatry; 2018 Mar; 175(3):251-261. PubMed ID: 29241359
[TBL] [Abstract][Full Text] [Related]
28. Heartbeat-Evoked Potential in Major Depressive Disorder: A Biomarker for Differential Treatment Prediction between Venlafaxine and rTMS?
Zwienenberg L; van Dijk H; Enriquez-Geppert S; van der Vinne N; Gevirtz R; Gordon E; Sack AT; Arns M
Neuropsychobiology; 2023; 82(3):158-167. PubMed ID: 36927872
[TBL] [Abstract][Full Text] [Related]
29. Auditory P3 in antidepressant pharmacotherapy treatment responders, non-responders and controls.
Jaworska N; De Somma E; Blondeau C; Tessier P; Norris S; Fusee W; Smith D; Blier P; Knott V
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1561-9. PubMed ID: 23664712
[TBL] [Abstract][Full Text] [Related]
30. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J
World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987
[TBL] [Abstract][Full Text] [Related]
31. Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder.
Korgaonkar MS; Williams LM; Song YJ; Usherwood T; Grieve SM
Br J Psychiatry; 2014 Oct; 205(4):321-8. PubMed ID: 24970773
[TBL] [Abstract][Full Text] [Related]
32. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.
Matrisciano F; Bonaccorso S; Ricciardi A; Scaccianoce S; Panaccione I; Wang L; Ruberto A; Tatarelli R; Nicoletti F; Girardi P; Shelton RC
J Psychiatr Res; 2009 Jan; 43(3):247-54. PubMed ID: 18511076
[TBL] [Abstract][Full Text] [Related]
33. EEG connectivity between the subgenual anterior cingulate and prefrontal cortices in response to antidepressant medication.
Iseger TA; Korgaonkar MS; Kenemans JL; Grieve SM; Baeken C; Fitzgerald PB; Arns M
Eur Neuropsychopharmacol; 2017 Apr; 27(4):301-312. PubMed ID: 28237506
[TBL] [Abstract][Full Text] [Related]
34. Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy.
Grosse L; Carvalho LA; Birkenhager TK; Hoogendijk WJ; Kushner SA; Drexhage HA; Bergink V
Psychopharmacology (Berl); 2016 May; 233(9):1679-88. PubMed ID: 25953327
[TBL] [Abstract][Full Text] [Related]
35. Neural correlates of treatment outcome in major depression.
Lisiecka D; Meisenzahl E; Scheuerecker J; Schoepf V; Whitty P; Chaney A; Moeller HJ; Wiesmann M; Frodl T
Int J Neuropsychopharmacol; 2011 May; 14(4):521-34. PubMed ID: 21205435
[TBL] [Abstract][Full Text] [Related]
36. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
Favré P
Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
[TBL] [Abstract][Full Text] [Related]
37. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
Cook IA; Hunter AM; Gilmer WS; Iosifescu DV; Zisook S; Burgoyne KS; Howland RH; Trivedi MH; Jain R; Greenwald S; Leuchter AF
J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
[TBL] [Abstract][Full Text] [Related]
38. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.
Trivedi MH; McGrath PJ; Fava M; Parsey RV; Kurian BT; Phillips ML; Oquendo MA; Bruder G; Pizzagalli D; Toups M; Cooper C; Adams P; Weyandt S; Morris DW; Grannemann BD; Ogden RT; Buckner R; McInnis M; Kraemer HC; Petkova E; Carmody TJ; Weissman MM
J Psychiatr Res; 2016 Jul; 78():11-23. PubMed ID: 27038550
[TBL] [Abstract][Full Text] [Related]
39. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Wang J; Liu X; Mullins CD
Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
[TBL] [Abstract][Full Text] [Related]
40. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Leelahanaj T
J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
